Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ASAP1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ASAP1 also known as DDEF1 stands for ADP-Ribosylation Factor GTPase-Activating Protein 1 and has a molecular weight of approximately 130 kDa. It plays a mechanical role in actin cytoskeleton remodeling by regulating ARF (ADP-ribosylation factor) GTPases. These are involved in intracellular vesicular transport. ASAP1 localizes to the cytoplasm and shows high expression in invasive cancer cell lines with noticeable expression noted in tissues such as the brain liver and lung.
Biological function summary
ASAP1 interacts with components of the focal adhesion complex a group of proteins critical in signaling pathways that connect the extracellular matrix and the actin cytoskeleton. It modulates cell adhesion migration and invasion. ASAP1 binds to proteins like paxillin which further influences the dynamics of actin and membrane trafficking important for cellular rearrangements.
Pathways
ASAP1 plays roles in actin cytoskeleton reorganization pathways and integrin-mediated signaling pathways. These pathways are essential for cell motility and shape. In these contexts ASAP1 interacts with cortactin an actin-binding protein involved in the regulation of cytoskeletal dynamics necessary for the migration and invasion of cancer cells.
ASAP1 has associations with cancer progression particularly in breast and colorectal cancer. Research indicates that elevated ASAP1 expression correlates with aggressive tumor behavior and poor prognosis. Its interaction with paxillin during disease conditions highlights its involvement in tumor invasiveness and metastasis highlighting its potential as a therapeutic target in oncology.
